» Articles » PMID: 20026497

Neonatal Screening for Treatable and Untreatable Disorders: Prospective Parents' Opinions

Overview
Journal Pediatrics
Specialty Pediatrics
Date 2009 Dec 23
PMID 20026497
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: In the Netherlands, in 2007, the national newborn screening program was expanded from 3 to 17 disorders that met the World Health Organization's Wilson and Jungner screening criteria, especially regarding treatability. The decision of whether to add diseases to the program is generally based on experts' advice, whereas the opinion of those whom it concerns--prospective parents--remains unknown. In this study, we investigated the opinion of prospective parents concerning newborn screening for disorders that are incurable yet treatable to some extent or even untreatable.

Methods: A structured questionnaire that consisted of 3 parts in which similar questions were posed about treatable, less treatable, and untreatable childhood-onset disorders was posted on the Web site of a national pregnancy fair.

Results: A total of 1631 prospective parents filled out the questionnaire, 259 of whom were excluded. In contrast to current policy, respondents showed a positive attitude toward inclusion of less treatable (88%) or untreatable childhood-onset disorders (73%) within the national newborn screening program. Respondents who already had children at the time of completing the questionnaire were even more in favor of screening for especially untreatable disorders. The most important reason mentioned was to prevent a long diagnostic quest. Obtaining information to enable reproductive choices in future pregnancies was hardly mentioned.

Conclusions: Prospective parents in the Dutch population seem interested in newborn screening for untreatable childhood-onset disorders; therefore, we argue that additional debate of pros and cons is needed among policy makers, health care professionals, and consumers.

Citing Articles

Epidemiology of inherited metabolic disorders in newborn screening: insights from three years of experience in Southern Iran.

Salarian L, Ilkhanipoor H, Amirhakimi A, Afshar Z, Nahid S, Ardekani F Orphanet J Rare Dis. 2025; 20(1):84.

PMID: 40001143 PMC: 11853994. DOI: 10.1186/s13023-025-03602-w.


Newborn Screening by DNA-First: Systematic Evaluation of the Eligibility of Inherited Metabolic Disorders Based on Treatability.

Veldman A, Sikkema-Raddatz B, Derks T, van Karnebeek C, Kiewiet M, Mulder M Int J Neonatal Screen. 2025; 11(1.

PMID: 39846587 PMC: 11755635. DOI: 10.3390/ijns11010001.


Wilson and Jungner Revisited: Are Screening Criteria Fit for the 21st Century?.

Schnabel-Besson E, Mutze U, Dikow N, Horster F, Morath M, Alex K Int J Neonatal Screen. 2024; 10(3).

PMID: 39311364 PMC: 11417796. DOI: 10.3390/ijns10030062.


Patient preferences in genetic newborn screening for rare diseases: study protocol.

Martin S, Angolini E, Audi J, Bertini E, Bruno L, Coulter J BMJ Open. 2024; 14(4):e081835.

PMID: 38643010 PMC: 11056621. DOI: 10.1136/bmjopen-2023-081835.


Parents' views on accepting, declining, and expanding newborn bloodspot screening.

van der Pal S, Wins S, Klapwijk J, van Dijk T, Kater-Kuipers A, van der Ploeg C PLoS One. 2022; 17(8):e0272585.

PMID: 35980961 PMC: 9387838. DOI: 10.1371/journal.pone.0272585.